In our study, patients were treated with pembrolizumab monotherapy at a dose of 200 mg of body weight every 21 days, where all patients had metastatic disease, PD-L1 TPS ≥50%, ECOG (European Cooperative Oncology Group) status 0 or 1. The gene discussed is CD274; the disease is metastatic neoplasm.